Abciximab dosage and administration: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "__NOTOC__ {{Abciximab}} {{CMG}}; {{AE}} {{SS}}, {{PB}} ==Indications and Usage== Abciximab is indicated as an adjunct to percutaneous coronary intervention for the preve...")
 
 
(5 intermediate revisions by one other user not shown)
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Abciximab#Adult Indications and Dosage]]
{{Abciximab}}
{{CMG}}; {{AE}} {{SS}}, {{PB}}
 
==Indications and Usage==
 
Abciximab is indicated as an adjunct to [[percutaneous coronary intervention]] for the prevention of cardiac ischemic complications.
 
* In patients undergoing [[percutaneous coronary intervention]]
* In patients with [[unstable angina]] not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours
 
Safety and efficacy of Abciximab use in patients not undergoing percutaneous coronary intervention have not been established.
 
Abciximab is intended for use with aspirin and heparin and has been studied only in that setting, as described in CLINICAL STUDIES.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = REOPRO (ABCIXIMAB) INJECTION, SOLUTION [ELI LILLY AND COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=033d4c3b-4630-4256-b8f7-9ed5f15de9a3#nlm34067-9 | publisher =  | date =  | accessdate = }}</ref>
 
==References==
{{Reflist}}
 
{{FDA}}
 
[[Category:Drugs]]

Latest revision as of 01:50, 21 July 2014

Redirect to:

Retrieved from "https://www.wikidoc.org/index.php?title=Abciximab_dosage_and_administration&oldid=996266"